No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
520 |
4. Check minimum number of eventsNone |
520 |
5. Include endpointsNone |
520 |
6. Filter based on genotype QC (FinnGen only) |
520 |
Control definitions (FinnGen only)
- Control exclude
- H7_VISUALDISTBLIND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- H53
- Name in latin
- Aliae perturbationes visus binocularis
Similar endpoints
↥List of similar endpoints to
Other disorders of binocular vision
based on the number of shared cases.
Similar with more cases:
- Visual disturbances
- Visual disturbances and blindness
- Diseases of the eye and adnexa
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4069 | 2676 | 1389 |
| Only index persons | 3914 | 2593 | 1321 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.06 | 0.08 | 0.04 |
| Only index persons | 0.08 | 0.10 | 0.05 |
| Median age at first event (years) | |||
| Whole population | 24.72 | 24.46 | 25.21 |
| Only index persons | 25.18 | 24.84 | 25.85 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 520 | 398 | 122 |
| Unadjusted period prevalence (%) | 0.12 | 0.14 | 0.05 |
| Median age at first event (years) | 34.31 | 31.45 | 43.65 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 442
- Matched controls
- 4418
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H53.3
ICD-10 Finland
Other disorders of binocular vision
+∞
323.0
438
*
H51.1
ICD-10 Finland
Convergence insufficiency and excess
247.6
97.8
97
5
H53.2
ICD-10 Finland
Diplopia
170.6
44.7
46
*
H50.52
ICD-10 Finland
Exophoria
34.0
41.6
54
18
H53.1
ICD-10 Finland
Subjective visual disturbances
16.2
34.8
57
40
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.9
34.0
127
335
WX704
NOMESCO Finland
Intubation
6.3
28.2
80
150
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.9
23.7
70
137
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
8.6
21.7
48
62
WX725
NOMESCO Finland
Noninvasive ventilation
6.9
20.6
53
86
SPAT1324
SPAT
Screening procedure
2.9
19.8
149
658
SPAT1301
SPAT
No procedures
2.7
19.3
182
919
A02BC03
ATC
lansoprazole; oral
2.8
17.9
143
647
TPH04
NOMESCO Finland
Cathetrisation of vein
3.1
17.5
108
413
R51.80
ICD-10 Finland
Headache
3.1
17.4
111
434
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
3.7
17.2
80
247
SPAT1263
SPAT
Sampling
2.4
16.7
229
1379
N03AX12
ATC
gabapentin; oral
3.3
16.2
89
312
Z01.8
ICD-10 Finland
Other specified special examinations
2.8
15.8
121
529
H53.0
ICD-10 Finland
Amblyopia ex anopsia
88.3
15.7
17
*
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
3.3
15.4
84
292
WX720
NOMESCO Finland
Own respiration
6.3
14.0
37
63
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.9
13.0
55
155
-
ICD-10 Finland
NA
8.9
13.0
27
32
WX702
NOMESCO Finland
Supraglottic ventilation device
4.6
12.9
45
106
SHB00
NOMESCO Finland
Prepation and fitting of bite rail to mouth
2.9
12.8
84
330
SPAT1028
SPAT
Ultrasound examination of paranasal sinuses
3.9
12.7
54
153
A02BC05
ATC
esomeprazole; systemic
2.2
12.6
178
1046
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
2.2
12.3
170
987
H50.31
ICD-10 Finland
Intermittent exotropia
16.5
12.2
19
12
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
5.4
12.1
36
71
H53.4
ICD-10 Finland
Visual field defects
123.1
11.5
12
*
N06AX21
ATC
duloxetine; oral
3.1
11.3
65
234
HAMTE
NOMESCO Finland
NA
20.7
11.2
16
8
N02CC01
ATC
sumatriptan; nasal, systemic, rectal
2.5
11.0
98
455
G43.1
ICD-10 Finland
Migraine with aura [classical migraine]
3.4
11.0
54
173
R03BA08
ATC
ciclesonide; inhalant
3.4
10.8
54
175
R03AC02
ATC
salbutamol; inhalant
2.0
10.6
250
1765
SPAT1310
SPAT
Counselling related to known health issue
2.0
10.3
161
967
AA1AD
NOMESCO Finland
CT of head and brain
2.5
10.2
91
422
N02AX02
ATC
tramadol; systemic, rectal
2.0
10.0
161
978
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.3
10.0
50
163
R01AD58
ATC
fluticasone, combinations; inhalant, nasal
2.2
9.9
123
671
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.6
9.5
43
129
H50.51
ICD-10 Finland
Esophoria
30.7
9.4
12
*
N06AA09
ATC
amitriptyline; systemic
3.4
9.4
45
142
A02BA02
ATC
ranitidine; systemic
2.5
9.3
77
344
N03AG01
ATC
valproic acid; systemic, rectal
3.5
9.3
43
132
N06AX11
ATC
mirtazapine; oral
2.0
9.2
141
833
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
2.6
9.0
70
302
A45
ICPC
General and Unspecified, Observ/health educat/advice/diet
6.3
9.0
23
38
R42
ICD-10 Finland
Dizziness and giddiness
2.3
9.0
86
414
FM1DE
NOMESCO Finland
Doppler ultrasound examination of heart
3.4
8.9
43
137
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.2
8.8
46
155
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
3.2
8.7
46
156
H04.10
ICD-10 Finland
Dry eye syndrome
3.0
8.6
51
187
CEC10
NOMESCO Finland
Recession and resection of extraocular muscle
11.9
8.6
15
13
N06AB10
ATC
escitalopram; oral
2.1
8.5
114
636
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
3.2
8.5
45
153
N03AE01
ATC
clonazepam; systemic
3.9
8.5
34
93
A31
ICPC
General and Unspecified, Medical examin/health eval partial
5.5
8.4
24
46
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
+∞
8.4
8
*
SHA02
NOMESCO Finland
Correction of physiology of bite - basic therapy visit
2.9
8.2
51
192
XA800
NOMESCO Finland
Neuropsychological investigation
5.0
8.2
25
52
R01AD09
ATC
mometasone; nasal
1.8
8.1
213
1507
R03CC03
ATC
terbutaline; systemic
4.6
8.1
27
62
C07AB07
ATC
bisoprolol; oral
1.9
8.0
136
829
N03AF02
ATC
oxcarbazepine; oral
5.1
8.0
24
49
SAA04
NOMESCO Finland
Special inverstigation of mouth
3.4
8.0
38
120
SPAT1044
SPAT
Tympanometry
5.9
7.9
21
37
C07AA05
ATC
propranolol; systemic
2.1
7.8
102
562
R06AX27
ATC
desloratadine; oral
1.9
7.8
149
946
WZC10
NOMESCO Finland
Extensive specialist consultion with written report
3.8
7.7
31
85
SPAT1097
SPAT
Recording of ECG
2.6
7.7
56
233
G43.0
ICD-10 Finland
Migraine without aura [common migraine]
3.0
7.7
43
151
G44.2
ICD-10 Finland
Tension-type headache
2.3
7.6
75
363
R44
ICPC
Respiratory, Preventive immunization/medic
12.1
7.6
13
11
H50.2
ICD-10 Finland
Vertical strabismus
12.1
7.6
13
11
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
4.0
7.6
29
76
R03BA01
ATC
beclometasone; inhalant
2.5
7.6
63
280
XCK00
NOMESCO Finland
Perimetry
3.6
7.6
33
97
K07.60
ICD-10 Finland
Snapping jaw
3.2
7.6
38
125
N05CF01
ATC
zopiclone; oral
2.0
7.5
115
673
D07AB02
ATC
hydrocortisone butyrate; topical
1.9
7.4
136
850
SAA03
NOMESCO Finland
Extended examination of mouth
1.7
7.3
196
1383
R53
ICD-10 Finland
Malaise and fatigue
2.1
7.3
87
461
J01EA01
ATC
trimethoprim; systemic
1.9
7.2
118
707
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
2.5
7.2
55
234
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
3.3
7.2
35
113
H53.9
ICD-10 Finland
Visual disturbance, unspecified
8.1
7.2
15
19
SBB10
NOMESCO Finland
Teeth copy
2.8
7.0
44
166
R49.01
ICD-10 Finland
Functional dysphonia
5.6
7.0
19
35
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
3.4
7.0
32
99
N05AH04
ATC
quetiapine; oral
2.1
6.9
85
456
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
1.7
6.8
187
1319
Z96.1
ICD-10 Finland
Presence of intraocular lens
3.0
6.7
38
135
CEC00
NOMESCO Finland
Recession of extraocular muscle
12.5
6.6
11
9
Z04.9
ICD-10 Finland
Examination and observation for unspecified reason
4.2
6.5
23
57
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
4.8
6.5
20
43
CS5Z4
NOMESCO Finland
Specialised imaging for glaucoma
7.6
6.5
14
19
H02AB06
ATC
prednisolone; systemic
1.7
6.5
191
1373
-1
NOMESCO Finland
NA
1.7
6.4
176
1237
N05BA04
ATC
oxazepam; oral
1.9
6.4
105
624
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
2.0
6.4
83
453
R03AK08
ATC
formoterol and beclometasone; inhalant
4.1
6.4
23
58
N05BA01
ATC
diazepam; systemic, rectal
2.3
6.4
56
258
M25.5
ICD-10 Finland
Pain in joint
1.8
6.4
126
801
XPX04
NOMESCO Finland
Angioscopy
27.1
6.2
8
*
WX234
NOMESCO Finland
Paracervical blockade
3.4
6.2
28
86
SPAT1240
SPAT
Therapeutic discussion
2.1
6.2
68
348
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
7.8
6.2
13
17
SPAT1260
SPAT
Consultation of another employee
2.0
6.1
83
461
A11
ICPC
Chest pain NOS
3.2
6.1
30
98
SPAT1081
SPAT
Cardiorespiratory global assessment
3.6
6.1
26
76
A02BC04
ATC
rabeprazole; oral
2.6
6.1
43
177
G40.20
ICD-10 Finland
Complex partial seizures with only alteration of consciousness
10.2
6.1
11
11
F32.9
ICD-10 Finland
Depressive episode, unspecified
2.1
6.0
73
388
N06CA01
ATC
amitriptyline and psycholeptics; systemic
2.6
6.0
42
170
M01AH03
ATC
valdecoxib; oral
3.2
6.0
29
94
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
70
166
4.72
27.95
4.8
8.7
23.7
24.5
mmol/l
0.91
64
155
145
575
3.11
27.23
3.5
2.9
37.9
208.2
ng/l
1.95
74
343
72
179
4.51
27.09
2.7
2.4
67.6
115.9
ng/l
1.13
65
154
194
934
2.72
25.13
4.0
3.2
1.0
1.0
kg/l
0.08
21
123
213
1137
2.48
21.62
2.8
2.3
53.5
55.6
u/l
0.37
203
1060
89
326
3.09
18.66
2.0
1.8
—
—
—
0
0
73
240
3.38
18.28
4.0
9.4
126.1
122.7
g/l
0.76
67
231
86
319
3.03
17.59
1.9
1.7
—
—
—
0
0
77
283
3.02
15.95
3.9
8.5
2.1
1.2
mmol/l
1.24
51
219
173
942
2.25
15.83
3.0
1.9
115.8
249.1
u/l
1.18
165
890
229
1409
2.12
15.25
6.7
4.0
36.8
36.8
g/l
0.08
220
1324
306
2122
2.07
14.51
4.3
4.1
6.1
6.4
mmol/l
1.44
265
1897
99
441
2.54
14.11
1.9
2.3
28.2
29.2
s
1.09
90
430
386
2956
2.19
13.60
4.8
3.6
10.1
9.3
mm/h
0.60
379
2764
247
1611
2.02
13.60
6.0
5.8
1.2
1.2
mmol/l
0.92
215
1358
267
1860
1.90
11.47
5.3
5.2
9.5
10.2
umol/l
0.88
257
1765
81
361
2.47
11.42
6.7
5.3
—
—
—
0
0
372
2901
1.99
11.21
7.4
6.3
69.8
73.6
u/l
1.82
360
2721
312
3846
0.53
10.86
9.5
9.0
90.6
92.0
ml/min/173m2
0.57
242
3018
98
492
2.22
10.48
2.1
1.9
—
—
—
0
0
69
300
2.50
10.22
1.5
1.3
119.8
171.1
u/ml
0.75
62
278
22
50
4.55
9.16
1.7
1.5
—
—
—
0
0
55
226
2.60
9.14
1.6
1.6
—
—
—
0
0
201
1356
1.79
8.95
4.3
2.8
25.3
29.0
u/l
2.22
195
1300
409
3414
1.93
8.58
5.2
4.0
14.5
14.4
pmol/l
0.39
390
3169
17
33
5.29
8.46
1.1
1.6
—
—
—
0
0
28
84
3.47
8.05
2.7
1.8
13.6
13.2
%
0.64
28
84
13
21
6.32
7.74
3.1
2.2
—
—
—
0
0
229
1657
1.68
7.62
4.1
3.1
—
—
—
0
0
43
938
0.41
7.60
2.3
1.9
—
—
—
0
0
205
1443
1.69
7.55
4.5
5.3
1.2
1.2
mmol/l
1.18
194
1320
90
496
1.98
7.41
3.1
3.2
0.8
0.8
mmol/l
0.08
84
467
464
4110
2.20
7.37
15.2
10.5
139.7
139.6
mmol/l
0.83
457
4000
286
2216
1.65
7.13
3.3
2.8
80.8
79.7
ug/l
0.05
280
2079
464
4126
2.16
7.03
15.3
10.6
3.9
3.9
mmol/l
0.03
457
4001
80
440
1.97
6.60
2.2
2.2
6805.4
4832.4
u/l
0.27
22
183
274
2130
1.61
6.52
4.0
3.1
0.0
0.0
estimate
0.50
33
418
113
698
1.79
6.50
1.5
1.6
138679733.8
42182834.2
pmol/l
0.47
106
614
270
2099
1.60
6.37
4.0
3.0
0.0
0.0
estimate
0.00
33
422
144
958
1.70
6.36
2.4
2.0
2.2
2.8
mg/l
3.36
135
810
62
315
2.10
6.35
3.7
3.4
4.7
4.6
pmol/l
0.51
57
278
18
47
3.93
6.31
1.2
1.5
—
—
—
0
0
447
3966
1.91
6.16
6.1
4.6
1.7
2.1
mu/l
0.56
434
3727
183
1308
1.62
6.06
1.8
1.7
96.9
96.7
pmol/l
0.01
89
697
472
4289
2.09
5.72
15.1
10.3
18.8
20.1
mg/l
0.42
374
3288
51
254
2.12
5.50
1.8
2.1
—
—
—
0
0
68
377
1.92
5.47
2.0
1.8
361.3
380.4
nmol/l
0.30
62
356
266
2108
1.54
5.45
5.3
4.2
0.0
0.0
estimate
0.50
34
432
53
269
2.08
5.45
1.6
1.7
—
—
—
0
0
116
764
1.67
5.22
1.3
1.3
21.0
29.2
iu/ml
0.63
47
236
18
54
3.42
5.21
1.2
1.5
—
—
—
0
0
12
28
4.36
4.85
1.1
1.1
1.0
1.2
u/l
—
6
14
284
2319
1.50
4.82
10.3
8.2
4.0
4.0
e9/l
0.23
269
2038
28
115
2.52
4.71
1.5
2.0
—
—
—
0
0
82
507
1.73
4.63
1.6
1.6
1208.8
1180.1
nmol/l
0.13
73
401
22
81
2.79
4.57
1.3
1.5
—
—
—
0
0
56
310
1.90
4.53
1.4
1.5
—
—
—
0
0
46
238
2.02
4.51
1.5
1.5
—
—
—
0
0
110
743
1.61
4.43
1.2
1.3
8.2
7.9
u/ml
0.01
47
294
43
220
2.04
4.35
1.4
1.4
—
—
—
0
0
12
31
3.94
4.28
1.2
1.1
—
—
—
0
0
247
1996
1.45
4.22
5.9
4.0
—
—
—
0
0
14
41
3.48
4.21
1.1
1.1
—
—
—
0
0
14
41
3.48
4.21
1.1
1.1
—
—
—
0
0
21
83
2.59
3.84
1.3
1.5
—
—
—
0
0
89
598
1.59
3.64
2.7
1.8
—
—
—
0
0
16
388
0.39
3.55
1.9
1.5
—
—
—
0
0
477
4471
1.81
3.48
10.9
8.2
25.0
25.1
u/l
0.04
472
4336
14
357
0.38
3.48
1.8
1.4
—
—
—
0
0
14
356
0.38
3.46
1.7
1.4
—
—
—
0
0
14
356
0.38
3.46
1.8
1.4
—
—
—
0
0
14
355
0.38
3.44
1.7
1.4
—
—
—
0
0
423
3856
1.52
3.41
4.0
3.5
5.6
5.7
mmol/l
1.13
407
3586
8
14
5.78
3.35
1.6
2.0
82.5
60.5
ug/l
—
8
14
418
3807
1.50
3.33
19.2
12.5
13.4
13.4
%
0.64
410
3744
12
38
3.21
3.23
1.1
1.1
—
—
—
0
0
129
963
1.45
3.20
1.9
1.7
1.4
1.3
mmol/l
0.41
124
834
29
533
0.52
3.07
2.7
2.5
1.3
3.2
e6/l
2.49
14
285
27
133
2.09
3.07
2.2
1.9
2.3
5.1
iu/l
1.82
13
53
149
1154
1.41
3.01
3.3
2.9
2.3
2.4
mmol/l
3.19
140
1043
335
2955
1.38
3.01
3.3
2.8
35.2
37.3
u/l
0.37
326
2829
120
895
1.44
2.98
1.9
1.9
1.0
0.9
mg/l
0.07
93
659
43
253
1.76
2.92
2.1
3.7
2.1
1.7
mmol/l
0.33
30
197
104
760
1.46
2.87
1.4
1.4
19.9
21.0
nmol/l
0.33
98
662
198
1619
1.36
2.85
2.7
2.2
75.6
74.2
nmol/l
0.29
190
1488
8
19
4.26
2.68
1.0
1.1
—
—
—
0
0
143
1124
1.38
2.61
1.6
1.5
—
—
—
0
0
385
3508
1.38
2.59
4.4
4.4
37.1
38.0
mmol/mol
1.70
378
3306
143
1129
1.37
2.53
4.6
3.3
0.0
0.0
estimate
1.08
33
427
158
1276
1.34
2.40
1.8
1.6
—
—
—
0
0
17
77
2.25
2.40
2.0
1.5
6.4
7.4
mmol/l
1.26
11
51
8
22
3.68
2.37
1.1
1.1
1880.5
1328.2
miu/ml
—
8
22
62
424
1.52
2.37
1.1
1.2
56.5
173.3
iu/ml
4.89
29
178
7
17
4.16
2.36
1.3
1.1
—
—
—
0
0
62
425
1.52
2.34
1.4
1.4
—
—
—
0
0
25
134
1.91
2.31
2.6
2.0
—
—
—
0
0
10
36
2.81
2.21
1.1
1.2
—
—
—
0
0
17
80
2.16
2.21
1.2
1.1
—
—
—
0
0
17
82
2.11
2.09
4.0
3.4
3.9
3.8
mmol/l
0.28
17
74
9
32
2.84
2.01
1.1
1.1
—
1.1
—
0
16
91
1170
0.73
1.99
2.3
2.3
—
—
—
0
0
12
51
2.38
1.96
1.4
1.1
—
—
—
0
0
145
1190
1.30
1.93
1.4
1.3
0.6
1.9
u/ml
1.86
31
328
97
751
1.36
1.92
2.7
1.9
—
—
—
0
0
105
830
1.33
1.82
2.9
4.0
4.2
12.2
mg/mmol
2.28
65
516
11
47
2.37
1.78
1.5
1.3
0.4
0.4
nmol/l
0.13
11
42
143
1184
1.29
1.76
3.0
2.9
11.8
32.1
ng/l
2.82
64
608
6
18
3.36
1.75
1.8
1.2
—
—
—
0
0
5
13
3.87
1.72
1.0
3.2
150.8
194.0
u/l
—
5
13
8
31
2.60
1.66
1.1
1.9
—
—
—
0
0
7
25
2.82
1.65
1.0
1.0
—
—
—
0
0
76
971
0.75
1.58
2.7
2.5
0.3
0.3
e6/l
0.24
59
706
34
227
1.53
1.51
3.5
6.3
5.7
8.0
mmol/l
3.08
34
219
9
37
2.46
1.48
1.0
1.1
—
—
—
0
0
37
257
1.47
1.38
3.6
2.2
66.9
76.4
ml/min/173m2
0.90
13
92
86
1060
0.77
1.37
2.1
2.1
—
—
—
0
0
5
17
2.96
1.36
1.2
1.2
—
—
—
0
0
419
3986
1.26
1.31
3.8
3.5
4.7
4.7
mmol/l
0.00
407
3760
56
424
1.36
1.31
2.1
2.1
22.3
24.7
%
0.44
27
368
56
424
1.36
1.31
4.9
3.8
19.8
21.9
%
0.46
13
177
14
76
1.87
1.31
1.2
1.2
—
—
—
0
0
381
3589
1.23
1.30
3.7
3.8
—
—
—
0
0
21
327
0.63
1.29
1.8
1.6
—
—
—
0
0
8
37
2.18
1.22
1.1
1.8
—
—
—
0
0
22
331
0.65
1.18
2.7
2.8
—
—
—
0
0
8
154
0.51
1.15
1.9
1.5
—
—
—
0
0
0
36
0.00
1.14
0.0
1.4
—
—
—
0
0
435
4176
1.25
1.13
18.0
11.0
40.4
40.2
%
0.24
298
3396
38
511
0.72
1.13
1.4
1.5
—
—
—
0
0
11
59
1.88
1.08
1.1
1.2
—
—
—
0
0
15
91
1.67
1.01
1.9
1.7
7.7
7.3
mmol/l
—
5
55
17
260
0.64
1.00
1.9
2.2
32.6
41.3
u/ml
0.18
17
246
0
29
0.00
0.98
0.0
1.1
—
—
—
0
0
0
30
0.00
0.97
0.0
1.5
—
—
—
0
0
14
219
0.63
0.92
1.6
1.7
2.8
3.3
mg/l
—
7
139
6
30
2.01
0.87
1.0
1.6
—
—
—
0
0
14
88
1.61
0.85
1.2
1.4
—
—
—
0
0
8
46
1.75
0.83
1.1
1.4
—
—
—
0
0
8
47
1.71
0.81
1.4
1.3
—
—
—
0
0
418
4034
1.18
0.80
4.2
3.8
2.8
2.8
mmol/l
0.19
402
3779
0
24
0.00
0.79
0.0
1.4
—
—
—
0
0
0
25
0.00
0.79
0.0
1.7
—
—
—
0
0
18
123
1.48
0.78
1.9
3.2
101.2
93.9
%
0.78
18
115
24
175
1.39
0.76
1.4
1.7
—
—
—
0
0
12
184
0.64
0.75
1.8
3.6
5.4
5.1
kpa
1.07
12
170
16
108
1.50
0.74
1.4
1.3
—
22.3
—
0
8
11
68
1.63
0.72
1.3
1.4
—
—
—
0
0
19
135
1.42
0.70
1.3
1.2
—
—
—
0
0
13
85
1.54
0.69
5.7
2.2
12.2
10.6
g/l
—
6
77
7
117
0.59
0.68
1.9
9.6
26.6
24.3
mmol/l
—
7
109
51
425
1.22
0.64
2.7
2.6
5.9
7.3
umol/l
0.31
41
357
410
3974
1.15
0.63
3.7
3.5
1.4
1.5
mmol/l
1.57
394
3733
8
49
1.64
0.62
1.3
1.8
—
—
—
0
0
0
20
0.00
0.60
0.0
1.9
—
—
—
0
0
0
20
0.00
0.60
0.0
1.9
—
—
—
0
0
0
20
0.00
0.60
0.0
1.9
—
—
—
0
0
0
20
0.00
0.60
0.0
1.9
—
—
—
0
0
0
22
0.00
0.59
0.0
1.4
—
21.8
—
0
22
11
73
1.52
0.56
2.3
2.1
—
—
—
0
0
8
55
1.46
0.56
1.9
1.1
—
—
—
0
0
6
39
1.54
0.53
1.5
1.1
—
—
—
0
0
6
40
1.51
0.51
1.5
1.1
—
—
—
0
0
16
118
1.37
0.50
1.2
1.1
0.7
1.2
u/ml
—
8
45
27
218
1.25
0.47
1.9
1.5
—
—
—
0
0
12
85
1.42
0.47
1.1
1.2
1.3
1.9
u/ml
—
6
31
48
553
0.85
0.45
2.5
2.3
0.5
0.8
e6/l
1.58
32
305
25
303
0.82
0.41
2.6
2.6
0.7
0.7
ug/l
—
9
179
9
70
1.29
0.37
1.3
2.2
—
—
—
0
0
14
179
0.78
0.36
1.6
1.4
—
—
—
0
0
6
44
1.37
0.34
1.2
1.2
9.3
13.3
u/l
—
6
39
11
82
1.35
0.34
1.3
1.1
—
—
—
0
0
7
54
1.30
0.30
1.4
1.5
20.8
38.2
nmol/l
—
7
48
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
7
56
1.25
0.29
7.4
4.5
0.4
0.3
u/ml
—
7
30
7
56
1.25
0.29
1.3
1.1
—
—
—
0
0
16
130
1.24
0.29
1.0
1.2
—
—
—
0
0
16
130
1.24
0.29
1.0
1.2
—
—
—
0
0
12
94
1.28
0.28
6.1
2.2
—
—
—
0
0
9
74
1.22
0.25
1.6
1.5
—
—
—
0
0
92
864
1.08
0.24
3.6
2.5
302.6
4640.1
umol/l
2.68
82
765
12
147
0.81
0.23
1.7
1.8
—
—
—
0
0
14
168
0.83
0.23
1.3
1.1
—
—
—
0
0
11
88
1.26
0.22
1.7
1.5
—
—
—
0
0
7
94
0.74
0.22
1.9
1.3
—
—
—
0
0
386
3800
1.06
0.22
3.2
3.2
1.3
1.2
mmol/l
0.90
370
3568
0
10
0.00
0.21
0.0
7.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
18.7
—
0
10
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.6
—
—
—
0
0
0
12
0.00
0.21
0.0
1.9
—
—
—
0
0
0
13
0.00
0.21
0.0
2.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
2.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.6
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
2.1
—
—
—
0
0
29
323
0.89
0.20
22.2
17.6
1.5
1.2
inr
—
5
53
6
52
1.16
0.19
1.8
1.5
—
—
—
0
0
17
196
0.86
0.19
1.4
1.4
—
—
—
0
0
16
138
1.16
0.17
1.6
1.4
—
—
—
0
0
69
651
1.07
0.17
1.6
1.5
—
—
—
0
0
10
82
1.22
0.17
1.0
1.1
—
—
—
0
0
10
83
1.21
0.15
2.1
2.1
307.3
274.3
ug/l
—
10
78
129
1249
1.04
0.14
3.1
2.8
—
—
—
0
0
29
314
0.92
0.13
1.2
1.0
—
—
—
0
0
27
253
1.07
0.08
1.2
1.3
88.1
271.6
miu/ml
—
10
129
11
122
0.90
0.07
1.4
1.3
—
7.7
—
0
20
8
91
0.88
0.07
1.3
1.2
—
—
—
0
0
58
590
0.98
0.02
1.5
1.7
1.3
1.3
%
0.08
51
545
10
107
0.93
0.02
1.1
1.3
—
—
—
0
0
71
701
1.01
0.02
2.3
3.0
346.9
923.0
ng/l
4.99
62
567
33
324
1.02
0.00
1.2
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
6.6
—
—
—
0
0
5
56
0.89
0.00
1.2
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
5.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
3.1
—
0
5
6
59
1.02
0.00
1.7
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
3.4
—
0.6
—
0
5
0
6
0.00
0.00
0.0
1.0
—
12.7
—
0
6
7
71
0.99
0.00
1.4
2.6
27.6
24.9
mmol/l
—
7
61
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint H7_BINODISTOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_BINODISTOTH | 1.046 [0.84, 1.31] | 0.695 |
| Birth year | 0.997 [0.99, 1.01] | 0.575 |
During the follow-up period (1.1.1998 — 31.12.2019), 105 out of 2492 females with H7_BINODISTOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_BINODISTOTH | 1.139 [0.89, 1.45] | 0.291 |
| Birth year | 0.988 [0.98, 1.0] | 0.013 |
During the follow-up period (1.1.1998 — 31.12.2019), 93 out of 1296 males with H7_BINODISTOTH died.
Mortality risk
Mortality risk for people of age
years, who have H7_BINODISTOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.112% | 0.227% |
| 5 | 0.569% | 1.355% |
| 10 | 1.518% | 3.457% |
| 15 | 3.118% | 6.739% |
| 20 | 5.849% | 11.563% |
Relationships between endpoints
↥Index endpoint: H7_BINODISTOTH – Other disorders of binocular vision
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data